|View printer-friendly version|
Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers
"It is clear that new treatment options are needed for patients with relapsed and refractory lymphoma, chronic lymphocytic leukemia and other lymphoproliferative disorders," said
PRT2070 is an oral, potent inhibitor of both the B-cell receptor (BCR) pathway via Syk and key JAK-mediated cytokines. These two pathways promote survival and proliferation of hematologic cancers, such as non-Hodgkin's lymphoma (
An estimated 560,000 people in
About the PRT2070 Phase 1/2 Study
The open-label, multicenter, Phase 1/2 proof-of-concept study is assessing the safety, pharmacokinetics, pharmacodynamics and clinical activity of oral PRT2070. In the multi-dose, dose-escalation Phase 1 part of the study, PRT2070 is being administered to sequential dose cohorts at increasing dose levels until the maximum tolerated dose is identified. This portion of the study can include patients with relapsed or refractory CLL/small lymphocytic lymphoma and
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the use of PRT2070 as a kinase inhibitor and Portola's Phase1/2 proof-of-concept study for PRT2070. Risks that contribute to the uncertain nature of the forward-looking statements include: the accuracy of Portola's estimates regarding its ability to initiate and/or complete its clinical trials; the success of Portola's clinical trials and the demonstrated efficacy of Portola's product candidates thereunder; the accuracy of Portola's estimates regarding its expenses and capital requirements; regulatory developments in
*PRT4445 has a proposed International Nonproprietary Name (pINN) of andexanet alfa.
i http://www.lls.org/#/diseaseinformation/lymphoma/nonhodgkinlymphoma/incidence. Accessed 10/24/13.